Why this trial matters : First ADC to move into the 1L HER2+ metastatic setting Breaks a decade-long treatment paradigm in first-line breast cancer care Confirms ADCs as frontline platforms, not just late-line salvage therapies Roche Giredestrant Delivers the First Phase III Win for an Oral SERD in Early Breast Cancer Roches oral SERD giredestrant reduced the risk of invasive disease recurrence versus standard endocrine therapy in the Phase III lidERA trial in ER-positive, HER2-negative early breast cancer, marking the first major advance in adjuvant endocrine therapy in decades
Exploring peptides for gut health provides comprehensive guidance on gastrointestinal applications
However, retatrutide is earlier in clinical development and not yet available
Nutrients 14(10):2153 Zou T, Xie F, Liang P, Chen J, Wang Z, Du M et al (2023) Polysaccharide-rich fractions from Enteromorpha prolifera improve hepatic steatosis and gut barrier integrity in high-fat diet-induced obese mice linking to modulation of gut microbiota
This is why his patented skin delivery is so critical, because it raises the RBC levels in 15 mins
Good results with the product
